Anti-Inflammation, Allergy Relief, and Brain Protection

How this yellow plant flavonoid fights inflammation, calms allergic reactions, and protects the aging brain

Luteolin is a yellow flavonoid found in everyday herbs and vegetables — celery, parsley, thyme, chamomile, and rosemary — that has become one of the more intensively studied plant compounds for reducing inflammation. It works on multiple fronts simultaneously: quieting the NF-κB inflammatory pathway, stabilizing mast cells to reduce allergic reactions, and protecting neurons from the kind of chronic, low-grade inflammation associated with cognitive decline [1][2][3]. Most people get modest amounts from food; concentrated supplements are used for more targeted anti-inflammatory or allergy support.

How Luteolin Works

Luteolin belongs to the flavone subclass of flavonoids and has a particularly broad range of biological activities. Its versatility comes from its ability to act on multiple signaling pathways at once, which is both what makes it interesting and what makes it challenging to study clinically.

Anti-Inflammatory Mechanisms

The main pathway luteolin affects is NF-κB (nuclear factor kappa B), a master regulator of inflammatory gene expression. In response to triggers like bacterial toxins, injury, or oxidative stress, NF-κB normally moves into the cell nucleus and switches on production of pro-inflammatory cytokines — including TNF-α, IL-1β, IL-6, and COX-2. Luteolin blocks this sequence by preventing the degradation of IκB-α, the protein that normally keeps NF-κB inactive in the cytoplasm [6].

Beyond NF-κB, luteolin also inhibits the AP-1 pathway (another inflammatory transcription factor) and reduces production of reactive oxygen species that would otherwise amplify the inflammatory signal [1]. This multi-target action is characteristic of plant polyphenols and may explain why they tend to produce more diffuse rather than highly specific effects.

Mast Cell Stabilization for Allergy Relief

Mast cells are the immune cells at the frontline of allergic reactions — when they detect allergens, they release histamine, leukotrienes, and prostaglandins that produce the familiar symptoms of hay fever, hives, and food sensitivity reactions. Luteolin stabilizes mast cells by blocking calcium influx into the cell and inhibiting protein kinase C activation, both of which are required for mast cell degranulation [2].

In human cultured mast cell studies, luteolin reduced histamine, leukotrienes, prostaglandin D2, and GM-CSF release in a concentration-dependent manner. Notably, it outperformed quercetin and baicalein (two other well-known flavonoids) in the same assay [2]. This makes it a scientifically grounded option alongside quercetin for people managing seasonal allergies or histamine intolerance. See our quercetin page for comparison.

Brain and Neuroprotective Effects

Neuroinflammation — chronic low-grade inflammation in the brain driven by activated microglia (the brain's immune cells) — is increasingly recognized as a central feature of cognitive decline and neurodegenerative conditions. Luteolin can cross the blood-brain barrier and accumulates in brain tissue, where it appears to suppress microglial activation and reduce production of brain-resident pro-inflammatory cytokines [3][4].

In animal models of memory impairment caused by reduced blood flow to the brain, luteolin treatment reversed learning and memory deficits, reduced TNF-α and IL-1β in the hippocampus, and restored long-term potentiation — the synaptic mechanism underlying memory formation — in treated animals [4]. This is one of the more compelling mechanistic links between a flavonoid and cognitive function, though it remains to be confirmed in human trials.

Food Sources

Luteolin is not as widely distributed as quercetin, but meaningful amounts are found in:

Celery and celery seed (among the richest sources)
Parsley (particularly fresh)
Thyme and other culinary herbs
Chamomile tea (which explains some of chamomile's calming effects)
Peppers (especially green bell peppers)
Artichoke hearts
Dandelion leaves
Rosemary and oregano

Dosage and Supplementation

Research has not established a well-validated human clinical dose. Animal studies typically use 20–100 mg/kg/day, which does not translate directly to human dosing. Supplement products typically range from 100–500 mg per capsule. Bioavailability from food or standard powder supplements is limited; some formulations combine luteolin with phosphatidylcholine (a "phytosome" form) to improve absorption, similar to approaches used with curcumin and quercetin.

For general anti-inflammatory or allergy support, many practitioners use 100–400 mg/day. Luteolin is generally considered safe; it has low acute toxicity in animal studies and has not shown significant adverse effects in the doses used in human cell studies. As with most flavonoids, avoid combining very high doses with blood-thinning medications without medical guidance.

Evidence Review

Anti-Inflammatory Pathways: Mechanistic Certainty, Clinical Gaps

The anti-inflammatory activity of luteolin is among the most mechanistically well-documented of any plant flavonoid. The 2018 systematic review by Aziz, Kim, and Cho (PMID 29801717), published in the Journal of Ethnopharmacology, synthesized findings from in vitro, in vivo (animal), and in silico (computational) studies. The review identified luteolin as targeting three distinct inflammatory signaling cascades: the Src/NF-κB pathway, the MAPK/AP-1 pathway, and the SOCS3/STAT3 pathway.

Chen et al. (PMID 17977562), published in Life Sciences, demonstrated that luteolin dose-dependently suppressed LPS-stimulated NF-κB p65 nuclear translocation and IκB-α degradation in alveolar macrophages, reducing downstream expression of iNOS, COX-2, and pro-inflammatory cytokines. This cell culture work established the core mechanistic framework that subsequent animal studies confirmed in vivo.

Limitation: Despite the mechanistic depth, there are currently few well-powered human clinical trials of luteolin alone for inflammatory conditions. Much of the human evidence comes from complex plant extracts containing multiple compounds, making it difficult to attribute effects specifically to luteolin. The 2018 review notes that clinical trials using formulated luteolin showed "excellent therapeutic effect against inflammation-associated diseases," but specific trial details and effect sizes from human populations are limited.

Mast Cell Stabilization: Human Cell Evidence

Kimata et al. (PMID 10718847), published in Clinical and Experimental Allergy, conducted a rigorous in vitro comparison of three flavonoids — luteolin, quercetin, and baicalein — in human cultured mast cells sensitized with IgE. Luteolin inhibited degranulation-induced release of histamine, sulfidopeptide leukotrienes, prostaglandin D2, and GM-CSF in a concentration-dependent fashion. At equimolar concentrations, luteolin was the most potent inhibitor of histamine and leukotriene release among the three compounds tested.

The mechanism was characterized as inhibition of Ca²⁺ influx and protein kinase C activation — the two intracellular signals required for mast cell degranulation — as well as suppression of ERK and JNK phosphorylation downstream. The use of human (rather than rodent) mast cells, sensitized with IgE to mimic actual allergic conditions, makes this study more directly applicable to human allergy management than most flavonoid mast cell research.

Important context: In vitro concentrations needed for these effects may not be fully achieved in target tissues through typical oral supplementation, though flavonoids do reach meaningful serum concentrations. The pharmacokinetics of luteolin in human mast cell tissue specifically have not been characterized in clinical trials.

Neuroprotection: Animal Models and Mechanistic Plausibility

Nabavi et al. (PMID 26361743), published in Brain Research Bulletin, reviewed luteolin's neuroprotective activity across multiple experimental systems. Key findings included:

Luteolin reduces amyloid-beta production and tau hyperphosphorylation in Alzheimer's cell and animal models
It inhibits acetylcholinesterase, the enzyme that breaks down acetylcholine (the same target as common Alzheimer's drugs)
It reduces oxidative stress in neurons through Nrf2 pathway activation and direct radical scavenging
Animal studies showed improvement in memory and learning tasks after luteolin supplementation

Yao et al. (PMID 29392519), published in Neurochemical Research, used a chronic cerebral hypoperfusion rat model — relevant to vascular dementia and age-related cognitive decline. Luteolin-treated animals showed significantly improved performance in the Morris water maze (measuring spatial memory) and novel object recognition tests. Hippocampal analysis revealed reduced microglia activation (OX-6+ cells), decreased pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and restored long-term potentiation amplitude. Effect sizes in the Morris water maze were substantial, with luteolin groups performing comparably to sham-operated controls rather than vehicle-treated impaired animals.

Limitation: All neuroprotection evidence is from animal models. While the mechanisms are plausible and the animal data is consistent, there are no published human clinical trials of luteolin for cognitive function or neurodegeneration. Human brain pharmacokinetics of luteolin — specifically how much reaches the hippocampus after oral dosing — have not been formally measured.

Cancer: Pre-Clinical Signals, No Clinical Trials

Lin et al. (PMID 18991571), published in Current Cancer Drug Targets, reviewed luteolin's anti-cancer mechanisms. In cell culture and animal studies, luteolin inhibited cancer cell proliferation across multiple cancer types (lung, breast, colon, prostate) by:

Inducing apoptosis via p53-dependent pathways and caspase activation
Suppressing PI3K/Akt and NF-κB survival signaling
Inhibiting matrix metalloproteinases involved in metastasis
Reducing VEGF-driven angiogenesis (blood vessel growth into tumors)

At the same time, the review noted that luteolin's behavior is context-dependent: in normal cells and pro-oxidant conditions, it can act as an antioxidant; in cancer cells with dysregulated redox signaling, it may act as a pro-oxidant, contributing to preferential cancer cell death.

Limitation: This is entirely pre-clinical evidence. No human trials have evaluated luteolin as a cancer treatment or preventive agent. Epidemiological associations between flavone-rich diets and reduced cancer risk exist but are confounded by other dietary factors. The cancer-relevant findings should not be interpreted as treatment evidence.

Overall Evidence Assessment

Luteolin has one of the strongest mechanistic evidence bases among plant flavonoids — particularly for anti-inflammatory and mast cell–stabilizing effects — but is behind quercetin in terms of human clinical trial data. The most clinically grounded application is allergy and histamine intolerance management, where human cell studies provide reasonable mechanistic confidence. Neuroprotective effects are compelling in animal models and mechanistically plausible, but human trials are needed. Bioavailability and tissue distribution in humans remain incompletely characterized. For those already benefiting from quercetin or managing neuroinflammation, luteolin is a well-rationalized complementary option — with appropriate expectations about the current depth of human clinical evidence.

References

Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studiesAziz N, Kim MY, Cho JY. Journal of Ethnopharmacology, 2018. PubMed 29801717 →
Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cellsKimata M, Shichijo M, Miura T, Serizawa I, Inagaki N, Nagai H. Clinical and Experimental Allergy, 2000. PubMed 10718847 →
Luteolin as an anti-inflammatory and neuroprotective agent: A brief reviewNabavi SF, Braidy N, Gortzi O, Sobarzo-Sanchez E, Daglia M, Skalicka-Wozniak K, Nabavi SM. Brain Research Bulletin, 2015. PubMed 26361743 →
Luteolin Could Improve Cognitive Dysfunction by Inhibiting NeuroinflammationYao ZH, Yao XL, Zhang Y, Zhang SF, Hu JC. Neurochemical Research, 2018. PubMed 29392519 →
Luteolin, a flavonoid with potential for cancer prevention and therapyLin Y, Shi R, Wang X, Shen HM. Current Cancer Drug Targets, 2008. PubMed 18991571 →
Luteolin suppresses inflammation-associated gene expression by blocking NF-kappaB and AP-1 activation pathway in mouse alveolar macrophagesChen CY, Peng WH, Tsai KD, Hsu SL. Life Sciences, 2007. PubMed 17977562 →